Accéder au contenu
Merck

AB5336P

Anti-α-Synuclein (SNCA) Antibody

CHEMICON®, sheep polyclonal

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement


A propos de cet article

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Clone:
polyclonal
Species reactivity:
rat, mouse, human
Application:
IHC
Citations:
8
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

Anti-Synuclein α Antibody, Chemicon®, from sheep

biological source

sheep

antibody form

affinity purified immunoglobulin

antibody product type

primary antibodies

clone

polyclonal

purified by

affinity chromatography

species reactivity

rat, mouse, human

manufacturer/tradename

Chemicon®

technique(s)

immunohistochemistry: suitable (paraffin)

NCBI accession no.

UniProt accession no.

shipped in

dry ice

target post-translational modification

unmodified

Quality Level

Gene Information

human ... SNCA(6622)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Immunogen

Synthetic peptide corresponding amino acids 108-120 of human alpha synuclein.

Application

Anti-Synuclein Antibody, α is an antibody against Synuclein for use in IH(P).
Immunohistochemistry: 1:1,000 on frozen or paraffin sections.

Optimal working dilutions must be determined by the end user.

Physical form

Affinity purified immunoglobulin. Lyophilized. Reconstitute with 50 μL of sterile distilled water. Centrifuge to remove any residue. Glycerol (1:1) can be added for additional stability.

Other Notes

Replaces: 04-1053

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

hcodes

Hazard Classifications

Aquatic Chronic 3

Classe de stockage

11 - Combustible Solids

wgk

WGK 3


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Mohamed-Bilal Fares et al.
Proceedings of the National Academy of Sciences of the United States of America, 113(7), E912-E921 (2016-02-04)
Lewy bodies (LBs) are intraneuronal inclusions consisting primarily of fibrillized human α-synuclein (hα-Syn) protein, which represent the major pathological hallmark of Parkinson's disease (PD). Although doubling hα-Syn expression provokes LB pathology in humans, hα-Syn overexpression does not trigger the formation
Avik Roy et al.
Scientific reports, 6, 22067-22067 (2016-02-27)
Ankyrin-rich BTB/POZ domain containing protein-2 or BPOZ-2, a scaffold protein, has been recently shown to control the degradation of many biological proteins ranging from embryonic development to tumor progression. However, its role in the process of neuronal diseases has not
Martial Kamdem Mbefo et al.
The Journal of biological chemistry, 290(15), 9412-9427 (2015-02-07)
Although α-synuclein (α-syn) phosphorylation has been considered as a hallmark of sporadic and familial Parkinson disease (PD), little is known about the effect of PD-linked mutations on α-syn phosphorylation. In this study, we investigated the effects of the A30P, E46K
Ayse Ulusoy et al.
The European journal of neuroscience, 32(3), 409-422 (2010-08-14)
Lewy bodies, which are a pathological hallmark of Parkinson's disease, contain insoluble polymers of alpha-synuclein (alphasyn). Among the different modifications that can promote the formation of toxic alphasyn species, C-terminal truncation is among the most abundant alterations in patients with
Cristiane Latge et al.
The Journal of biological chemistry, 290(33), 20527-20540 (2015-07-08)
Cerebral dopamine neurotrophic factor (CDNF) is a promising therapeutic agent for Parkinson disease. As such, there has been great interest in studying its mode of action, which remains unknown. The three-dimensional crystal structure of the N terminus (residues 9-107) of

Numéro d'article de commerce international

RéférenceGTIN
AB5336P04053252337574

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique